转移性前列腺癌细胞减灭治疗的研究进展

代龙国; 白宇

doi:10.12259/j.issn.2095-610X.S20230103

转移性前列腺癌细胞减灭治疗的研究进展

doi: 10.12259/j.issn.2095-610X.S20230103

代龙国,
白宇^,

云南省肿瘤医院泌尿外科，云南昆明　650118

基金项目: 国家自然科学基金资助项目（82160511）；国家癌症中心攀登基金资助项目（NCC201925B01）；昆明医科大学研究生教育创新基金资助项目（2022S082）

详细信息

作者简介:
代龙国（1996～），男，云南曲靖人，在读硕士研究生，主要从事泌尿生殖系统肿瘤的基础与临床研究工作

通讯作者:
白宇，E-mail：baiyuff@126.com

中图分类号: R737.25
计量
- 文章访问数: 3206
- HTML全文浏览量: 1997
- PDF下载量: 15
- 被引次数: 0
出版历程
- 收稿日期: 2022-11-15
- 网络出版日期: 2023-01-18
- 刊出日期: 2023-01-18

Research Progress of Cytoreductive Treatment for Metastatic Prostate Cancer

Longguo DAI,
Yu BAI^,

Dept. of Urinary Surgery，Yunnan Tumor Hospital，Kunming Yunnan 650118，China

摘要

摘要: 转移性前列腺癌（metastatic prostate cancer，mPCa）在单独使用全身治疗一段时间后会进展至去势抵抗状态。因此，越来越多的注意力集中在局部细胞减灭和/或转移导向治疗（metastasis-directed therapies，MDT）可能获得的生存益处上。在此背景下，已经探索了用放射治疗和根治性前列腺切除术（radical prostatectomy，RP）治疗原发肿瘤的方法，并提出了新型微创消融疗法。此外，有关MDT （主要是立体定向消融放射治疗）的潜在临床益处的证据正在积累。总结了当前mPCa患者细胞减灭治疗策略的证据基础。
- 转移性前列腺癌 /
- 细胞减灭治疗 /
- 消融治疗 /
- 放射治疗 /
- 前列腺切除术
Abstract: Metastatic prostate cancer （mPCa） will progress to castrate-resistant state after a period of androgen-deprivation therapy （ADT） alone. Therefore, increasing focus is being placed on the additional survival benefits that could potentially be achieved with local cytoreductive and/or metastasis-directed therapies （MDT）. Local treatment of the primary tumour with the established modalities of radiotherapy and radical prostatectomy has been explored in this context, and the use of novel minimally invasive ablative therapies has been proposed. In addition, evidence of the potential clinical benefits of MDT with ionizing radiation （primarily stereotactic ablative radiotherapy） is accumulating. This aticle summarizes the current evidence base for a cytoreductive strategy in patients with mPCa.
- Metastatic prostate cancer /
- Cytoreductive treatment /
- Ablative therapies /
- Radiotherapy /
- Prostatectomy

HTML全文

参考文献(26)

[1]	Siegel R L,Miller K D,Fuchs H E,et al. Cancer statistics,2022[J]. CA Cancer J Clin,2022,72(1):7-33. doi: 10.3322/caac.21708
[2]	Wang L,Paller C J,Hong H,et al. Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: A systematic review and network meta-analysis[J]. JAMA Oncol,2021,7(3):412-420. doi: 10.1001/jamaoncol.2020.6973
[3]	Cheng Q,Butler W,Zhou Y,et al. Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy[J]. Eur Urol,2022,81(5):446-455. doi: 10.1016/j.eururo.2021.12.039
[4]	Ranasinghe W,Chapin B F,Kim I Y,et al. The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer[J]. BJU Int,2020,125(6):792-800. doi: 10.1111/bju.15055
[5]	Püllen L,Sprave T,Hadaschik B,et al. [Local and metastasis-directed therapy for oligometastatic prostate cancer][J]. Aktuelle Urol,2021,52(2):149-154. doi: 10.1055/a-1328-9975
[6]	Boevé L M S,Hulshof M,Vis A N,et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: Data from the HORRAD trial[J]. Eur Urol,2019,75(3):410-418. doi: 10.1016/j.eururo.2018.09.008
[7]	Cho Y,Chang J S,Rha K H,et al. Does radiotherapy for the primary tumor benefit prostate cancer patients with distant metastasis at initial diagnosis?[J]. PLoS One,2016,11(1):e0147191. doi: 10.1371/journal.pone.0147191
[8]	Culp S H,Schellhammer P F,Williams M B. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study[J]. Eur Urol,2014,65(6):1058-1066. doi: 10.1016/j.eururo.2013.11.012
[9]	Parker C C,James N D,Brawley C D,et al. Radiotherapy to the primary tumour for newly diagnosed,metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial[J]. Lancet,2018,392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3
[10]	Rusthoven C G,Jones B L,Flaig T W,et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer[J]. J Clin Oncol,2016,34(24):2835-2842. doi: 10.1200/JCO.2016.67.4788
[11]	Gratzke C,Engel J,Stief C G. Role of radical prostatectomy in metastatic prostate cancer: Data from the munich cancer registry[J]. Eur Urol,2014,66(3):602-603. doi: 10.1016/j.eururo.2014.04.009
[12]	Sooriakumaran P,Karnes J,Stief C,et al. A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation[J]. Eur Urol,2016,69(5):788-794. doi: 10.1016/j.eururo.2015.05.023
[13]	Jang W S,Kim M S,Jeong W S,et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases?[J]. BJU Int,2018,121(2):225-231. doi: 10.1111/bju.13992
[14]	Shemshaki H,Al-mamari S A,Geelani I A,et al. Cytoreductive radical prostatectomy versus systemic therapy and radiation therapy in metastatic prostate cancer: A systematic review and meta-analysis[J]. Urologia,2022,89(1):16-30. doi: 10.1177/03915603211036631
[15]	Lumen N,De Bleser E,Buelens S,et al. The role of cytoreductive radical prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate cancer. Results from the local treatment of metastatic prostate cancer (LoMP) registry[J]. Eur Urol Open Sci,2021,29(6):68-76.
[16]	Heidenreich A,Pfister D,Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: Results of a feasibility and case-control study[J]. J Urol,2015,193(3):832-838. doi: 10.1016/j.juro.2014.09.089
[17]	Shah T T,Peters M,Eldred-evans D,et al. Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry[J]. Eur Urol,2019,76(1):98-105. doi: 10.1016/j.eururo.2018.12.030
[18]	Morkos J,Porosnicu Rodriguez K A,Zhou A,et al. Percutaneous cryoablation for stage 1 renal cell carcinoma: Outcomes from a 10-year prospective study and comparison with matched cohorts from the national cancer database[J]. Radiology,2020,296(2):452-459. doi: 10.1148/radiol.2020192325
[19]	Sheng M X,Wan L L,Liu C M,et al. Cytoreductive cryosurgery in patients with bone metastatic prostate cancer: A retrospective analysis[J]. Kaohsiung J Med Sci,2017,33(12):609-615. doi: 10.1016/j.kjms.2017.07.002
[20]	Reddy D,Peters M,Shah T T,et al. Cancer control outcomes following focal therapy using high-intensity focused ultrasound in 1379 men with nonmetastatic prostate cancer: A multi-institute 15-year experience[J]. Eur Urol,2022,81(4):407-413. doi: 10.1016/j.eururo.2022.01.005
[21]	Ishihara H,Takagi T,Kondo T,et al. Prognostic impact of metastasectomy in renal cell carcinoma in the postcytokine therapy era[J]. Urol Oncol,2021,39(1):77.e17-77.e25. doi: 10.1016/j.urolonc.2020.08.011
[22]	Parker C,Nilsson S,Heinrich D,et al. Alpha emitter radium-223 and survival in metastatic prostate cancer[J]. N Engl J Med,2013,369(3):213-223. doi: 10.1056/NEJMoa1213755
[23]	Ost P,Reynders D,Decaestecker K,et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective,randomized,multicenter phase II trial[J]. J Clin Oncol,2018,36(5):446-453. doi: 10.1200/JCO.2017.75.4853
[24]	O'shaughnessy M J,Mcbride S M,Vargas H A,et al. A pilot study of a multimodal treatment paradigm to accelerate drug evaluations in early-stage metastatic prostate cancer[J]. Urology,2017,102(4):164-172.
[25]	Radwan N,Phillips R,Ross A,et al. A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE)[J]. BMC Cancer,2017,17(1):453. doi: 10.1186/s12885-017-3455-6
[26]	Sartor O,De Bono J,Chi K N,et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer[J]. N Engl J Med,2021,385(12):1091-1103. doi: 10.1056/NEJMoa2107322

相关文章(20)

[1]	谢平波, 刘明生, 周红庆, 武绍梅, 邵涛, 郭峰. 经尿道前列腺电切术联合内分泌治疗晚期前列腺癌的效果分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231208
[2]	王芳, 赵蓉, 郑虹. 康复新联合蒙脱石散防治放射性口腔黏膜炎的临床疗效, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210626
[3]	张江, 刘燕, 李文辉, 赵喜娟, 陈正庭, 关琼瑶, 吴江. 睡前音乐疗法对乳腺癌放疗患者睡眠质量和癌因性疲乏的影响, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20201248
[4]	刘忠意, 侯杰. 鼻内镜下同步完成腺样体切除及鼓膜置管术治疗小儿分泌性中耳炎, 昆明医科大学学报.
[5]	沈洁, 官润云, 何宗海, 郑明星. PKRP与TmLRP治疗良性前列腺增生症的早期疗效及并发症, 昆明医科大学学报.
[6]	杨琳琳. 高危子宫内膜癌术后辅助同步放化疗与单纯放疗的临床对比, 昆明医科大学学报.
[7]	杨琳琳. 检测外周血CA125对同步放化疗治疗高危子宫内膜癌的意义, 昆明医科大学学报.
[8]	王顺军. 双石通淋胶囊治疗慢性细菌性前列腺炎的临床疗效观察, 昆明医科大学学报.
[9]	张劲松. 保留前列腺的根治性膀胱切除治疗肌层浸润性膀胱癌的适应症, 昆明医科大学学报.
[10]	孙建军. 胆囊切除术致胆管损伤28例治疗体会, 昆明医科大学学报.
[11]	曹绍党. 琥珀酸索利那新治疗经尿道前列腺电切术后患者尿失禁20例报道, 昆明医科大学学报.
[12]	柯坤彬. 晚期前列腺癌侵犯输尿管口的腔内姑息性治疗15例临床分析, 昆明医科大学学报.
[13]	刘晋宏. 塞来昔布治疗Ⅲb型前列腺炎的临床疗效观察, 昆明医科大学学报.
[14]	刘鹏杰. 内分泌治疗在89 SrCl2治疗前列腺癌骨转移中的作用, 昆明医科大学学报.
[15]	牛华涛. XRCC1在脑胶质瘤中的表达及与放疗的相关性研究, 昆明医科大学学报.
[16]	胡礼炳. 2012年欧洲泌尿外科学会睾丸肿瘤诊疗指南解读, 昆明医科大学学报.
[17]	阮殿省. 耻骨上前列腺摘除术治疗前列腺增生症98例临床分析, 昆明医科大学学报.
[18]	. 耻骨上前列腺摘除术治疗前列腺增生症98例临床分析, 昆明医科大学学报.
[19]	. 经尿道等离子电切术治疗良性前列腺增生98例报道, 昆明医科大学学报.
[20]	. 放射疗法联合唑来磷酸治疗癌性骨痛的临床观察, 昆明医科大学学报.